...
首页> 外文期刊>Cerebrovascular Diseases Extra >Autologous Mesenchymal Stem Cells in Chronic Stroke
【24h】

Autologous Mesenchymal Stem Cells in Chronic Stroke

机译:慢性中风的自体间充质干细胞

获取原文
           

摘要

Background: Cell transplantation is a ‘hype and hope’ in the current scenario. It is in the early stage of development with promises to restore function in chronic diseases. Mesenchymal stem cell (MSC) transplantation in stroke patients has shown significant improvement by reducing clinical and functional deficits. They are feasible and multipotent and have homing characteristics. This study evaluates the safety, feasibility and efficacy of autologous MSC transplantation in patients with chronic stroke using clinical scores and functional imaging (blood oxygen level-dependent and diffusion tensor imaging techniques). Methods: Twelve chronic stroke patients were recruited; inclusion criteria were stroke lasting 3 months to 1 year, motor strength of hand muscles of at least 2, and NIHSS of 4–15, and patients had to be conscious and able to comprehend. Fugl Meyer (FM), modified Barthel index (mBI), MRC, Ashworth tone grade scale scores and functional imaging scans were assessed at baseline, and after 8 and 24 weeks. Bone marrow was aspirated under aseptic conditions and expansion of MSC took 3 weeks with animal serum-free media (Stem Pro SFM). Six patients were administered a mean of 50–60 × 106 cells i.v. followed by 8 weeks of physiotherapy. Six patients served as controls. This was a non-randomized experimental controlled trial. Results: Clinical and radiological scanning was normal for the stem cell group patients. There was no mortality or cell-related adverse reaction. The laboratory tests on days 1, 3, 5 and 7 were also normal in the MSC group till the last follow-up. The FM and mBI showed a modest increase in the stem cell group compared to controls. There was an increased number of cluster activation of Brodmann areas BA 4 and BA 6 after stem cell infusion compared to controls, indicating neural plasticity. Conclusion: MSC therapy aiming to restore function in stroke is safe and feasible. Further randomized controlled trials are needed to evaluate its efficacy.
机译:背景:在目前的情况下,细胞移植是一种“炒作和希望”。它处于发展的初期,有望恢复慢性疾病的功能。中风患者的间充质干细胞(MSC)移植通过减少临床和功能缺陷已显示出显着改善。它们是可行的,多能的并且具有归巢特性。这项研究使用临床评分和功能成像(血氧水平依赖性和弥散张量成像技术)评估了慢性卒中患者自体MSC移植的安全性,可行性和有效性。方法:招募了12名慢性中风患者。入选标准为中风持续3个月至1年,手部肌肉的运动强度至少为2,NIHSS为4–15,患者必须有意识并能够理解。在基线时以及第8和24周后评估Fugl Meyer(FM),改良的Barthel指数(mBI),MRC,Ashworth音调等级量表评分和功能成像扫描。在无菌条件下抽吸骨髓,并用动物无血清培养基(Stem Pro SFM)扩张MSC,历时3周。六例患者平均接受了50-60×10 6 个细胞的静脉注射。然后进行8周的理疗。 6例作为对照。这是一项非随机的实验对照试验。结果:干细胞组患者的临床和放射学扫描正常。没有死亡率或细胞相关的不良反应。直到最后一次随访,MSC组第1、3、5和7天的实验室检查也正常。与对照组相比,FM和mBI显示干细胞组的适度增加。与对照相比,干细胞输注后Brodmann区BA 4和BA 6的簇激活数量增加,表明神经可塑性。结论:以恢复中风功能为目的的MSC治疗是安全可行的。需要进一步的随机对照试验来评估其疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号